Equities Analysts Set Expectations for TNYA FY2025 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of Tenaya Therapeutics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.55) for the year, up from their prior estimate of ($0.67). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q4 2025 earnings at ($0.06) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group reduced their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, March 13th. Morgan Stanley dropped their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a research report on Monday. Finally, Chardan Capital dropped their price objective on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics presently has an average rating of “Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Trading Up 4.0 %

Shares of NASDAQ TNYA opened at $0.57 on Thursday. The business’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $1.65. Tenaya Therapeutics has a 12-month low of $0.39 and a 12-month high of $5.10. The stock has a market cap of $49.56 million, a P/E ratio of -0.39 and a beta of 2.83.

Insider Buying and Selling

In related news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the transaction, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. The trade was a 262.62 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 19,621 shares of company stock worth $10,595 in the last 90 days. Company insiders own 32.76% of the company’s stock.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Tenaya Therapeutics by 204.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after acquiring an additional 226,466 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Tenaya Therapeutics by 61.9% in the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares in the last quarter. State Street Corp boosted its holdings in Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after purchasing an additional 9,506 shares in the last quarter. Spire Wealth Management acquired a new position in Tenaya Therapeutics during the 4th quarter worth approximately $53,000. Finally, Geode Capital Management LLC raised its stake in shares of Tenaya Therapeutics by 5.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock worth $2,502,000 after buying an additional 66,968 shares in the last quarter. 90.54% of the stock is owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.